FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214389889> ?p ?o ?g. }

• W3214389889 endingPage "803" @default.
• W3214389889 startingPage "803" @default.
• W3214389889 abstract "Abstract Genetic profiling of leukemic cells forms the basis for risk stratification in acute myeloid leukemia (AML). Genetic markers in AML are used to make recommendations for distinct treatment approaches, such as remission consolidation with chemotherapy rather than stem cell transplant for patients with favorable risk genetics as defined by the current guidelines from the European LeukemiaNet (ELN). Yet, several limitations remain, such as overall rarity of many mutations, hierarchical complexity in cases with multiple mutations, conflicting reports of associations with outcomes for some genetic markers, and the absence of markers with prognostic significance in some patients. We have recently described genome-wide DNA methylation signatures that underlie biological features of AML cells and their utility to classify patients [Giacopelli et al. Genome Res. 2021;31:747]. The additional value of epigenetic information for risk assessment in AML in the context of current genetic and other clinical prognostic markers remains largely unexplored. In this study, we have first developed a targeted approach for assessment of DNA methylation-based signatures and employed it to classify 1,262 patients with de novo AML enrolled onto the Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology studies. We successfully classified 87.5% of patients into one of 13 DNA methylation subgroups, termed 'epitypes' (Figure 1A,B). We found that epitypes are composed of a majority of patients with a specific genetic alteration (or a unique combination of alterations) in 9 of 13 epitypes. However, we also identified subgroups of patients that lack these highly recurrent alterations, and, instead, represent an epigenetic phenocopy of the dominant genetic feature (epiphenocopy). Epiphenocopies within epitypes were often enriched in specific lower frequency mutations, suggesting convergence of biological function(s) for these rare mutations. Epiphenocopying was also exhibited by patients displaying a DNA methylation signature involving hypomethylation of STAT DNA sequence motifs (termed the STAT hypomethylation signature, SHS) that mimicked FLT3-ITD mutations. Epitype and SHS DNA methylation signatures affected clinical outcomes separately to ELN risk groups (P&lt;0.0001; Figures 1C,D), and FLT3-ITD status (P&lt;0.0001; Figure 1E), respectively. To broadly examine the prognostic power of DNA methylation signatures, we combined methylation-based classifications into a knowledge bank containing a compendium of other prognostic markers. Using a recently developed machine-learning approach [Gerstung et al. Nat Genet. 2017;49(3):332], we found that DNA methylation retained a high degree of importance for clinical outcomes, including overall survival (Figure 1F). Specifically, SHS and 6 epitypes were the most significant features negatively associated with overall survival along with age (P&lt;0.0001; Figure 1G). SHS and epitype were among the most significantly associated features for all other endpoints, such as early death, remission and relapse (P&lt;0.0001) and improved concordance between all predicted to actual outcomes. Finally, we used DNA methylation to reconstruct all 4 genetic features that define the ELN Favorable risk group. We found that patients with epiphenocopies of t(8;21)/inv(16) (CBF-AML), and CEBPA-dm had favorable outcome indistinguishable from that of patients with the respective genetic markers. NPM1-mutated, FLT3-ITD-negative patients displaying SHS-positivity had adverse risk despite lacking FLT3-ITD. Re-classifying patients with CBF-AML and CEBPA-dm epiphenocopies from more unfavorable risk groups into favorable group and excluding KMT2A/MLL-like and SHS-positive patients substantially improves the definition of favorable risk AML (P&lt;0.0001; Figure 1H). Our study demonstrates that DNA methylation signatures advance our understanding of the biology of AML and improve risk stratification through the identification of patients with epiphenocopies that mimic genetic mutations and other biological features. Use of DNA methylation signatures may lead to more effective assignment of patients to existing and novel therapeutic approaches. Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org; ClinicalTrials.gov Identifiers: NCT00048958 (8461), NCT00899223 (9665), and NCT00900224 (20202) Figure 1 Figure 1. Disclosures Blachly: KITE: Consultancy, Honoraria; INNATE: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria. Blum: Abbvie: Honoraria; AmerisourceBergen: Honoraria; Celyad Oncology: Research Funding; Xencor: Research Funding; Nkarta: Research Funding; Forma Therapeutics: Research Funding; Leukemia and Lymphoma Society: Research Funding; Syndax: Honoraria. Stone: Agios Pharmaceuticals Inc, Novartis;: Research Funding; ACI Clinical, Syntrix Pharmaceuticals, Takeda Oncology: Other: Data Safety & Monitoring; AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, BerGenBio ASA, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Takeda Oncology: Other: Advisory Committee. Eisfeld: Karyopharm (spouse): Current Employment. Byrd: Novartis, Trillium, Astellas, AstraZeneca, Pharmacyclics, Syndax: Consultancy, Honoraria; Vincerx Pharmaceuticals: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Newave: Membership on an entity's Board of Directors or advisory committees." @default.
• W3214389889 created "2021-11-22" @default.
• W3214389889 creator A5000921376 @default.
• W3214389889 creator A5004524654 @default.
• W3214389889 creator A5030342776 @default.
• W3214389889 creator A5034265050 @default.
• W3214389889 creator A5040074924 @default.
• W3214389889 creator A5044008222 @default.
• W3214389889 creator A5044621991 @default.
• W3214389889 creator A5049910941 @default.
• W3214389889 creator A5053059878 @default.
• W3214389889 creator A5062108544 @default.
• W3214389889 creator A5063462224 @default.
• W3214389889 creator A5066837969 @default.
• W3214389889 creator A5069208658 @default.
• W3214389889 creator A5071023119 @default.
• W3214389889 creator A5074089943 @default.
• W3214389889 creator A5076516238 @default.
• W3214389889 creator A5080781659 @default.
• W3214389889 creator A5085998113 @default.
• W3214389889 creator A5086415198 @default.
• W3214389889 creator A5086647663 @default.
• W3214389889 creator A5088855223 @default.
• W3214389889 date "2021-11-05" @default.
• W3214389889 modified "2023-10-13" @default.
• W3214389889 title "Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)" @default.
• W3214389889 doi "https://doi.org/10.1182/blood-2021-147652" @default.
• W3214389889 hasPublicationYear "2021" @default.
• W3214389889 type Work @default.
• W3214389889 sameAs 3214389889 @default.
• W3214389889 citedByCount "0" @default.
• W3214389889 crossrefType "journal-article" @default.
• W3214389889 hasAuthorship W3214389889A5000921376 @default.
• W3214389889 hasAuthorship W3214389889A5004524654 @default.
• W3214389889 hasAuthorship W3214389889A5030342776 @default.
• W3214389889 hasAuthorship W3214389889A5034265050 @default.
• W3214389889 hasAuthorship W3214389889A5040074924 @default.
• W3214389889 hasAuthorship W3214389889A5044008222 @default.
• W3214389889 hasAuthorship W3214389889A5044621991 @default.
• W3214389889 hasAuthorship W3214389889A5049910941 @default.
• W3214389889 hasAuthorship W3214389889A5053059878 @default.
• W3214389889 hasAuthorship W3214389889A5062108544 @default.
• W3214389889 hasAuthorship W3214389889A5063462224 @default.
• W3214389889 hasAuthorship W3214389889A5066837969 @default.
• W3214389889 hasAuthorship W3214389889A5069208658 @default.
• W3214389889 hasAuthorship W3214389889A5071023119 @default.
• W3214389889 hasAuthorship W3214389889A5074089943 @default.
• W3214389889 hasAuthorship W3214389889A5076516238 @default.
• W3214389889 hasAuthorship W3214389889A5080781659 @default.
• W3214389889 hasAuthorship W3214389889A5085998113 @default.
• W3214389889 hasAuthorship W3214389889A5086415198 @default.
• W3214389889 hasAuthorship W3214389889A5086647663 @default.
• W3214389889 hasAuthorship W3214389889A5088855223 @default.
• W3214389889 hasConcept C104317684 @default.
• W3214389889 hasConcept C126322002 @default.
• W3214389889 hasConcept C143998085 @default.
• W3214389889 hasConcept C150194340 @default.
• W3214389889 hasConcept C151730666 @default.
• W3214389889 hasConcept C190727270 @default.
• W3214389889 hasConcept C203014093 @default.
• W3214389889 hasConcept C2778461978 @default.
• W3214389889 hasConcept C2778729363 @default.
• W3214389889 hasConcept C2779343474 @default.
• W3214389889 hasConcept C41091548 @default.
• W3214389889 hasConcept C54355233 @default.
• W3214389889 hasConcept C60644358 @default.
• W3214389889 hasConcept C71924100 @default.
• W3214389889 hasConcept C86803240 @default.
• W3214389889 hasConceptScore W3214389889C104317684 @default.
• W3214389889 hasConceptScore W3214389889C126322002 @default.
• W3214389889 hasConceptScore W3214389889C143998085 @default.
• W3214389889 hasConceptScore W3214389889C150194340 @default.
• W3214389889 hasConceptScore W3214389889C151730666 @default.
• W3214389889 hasConceptScore W3214389889C190727270 @default.
• W3214389889 hasConceptScore W3214389889C203014093 @default.
• W3214389889 hasConceptScore W3214389889C2778461978 @default.
• W3214389889 hasConceptScore W3214389889C2778729363 @default.
• W3214389889 hasConceptScore W3214389889C2779343474 @default.
• W3214389889 hasConceptScore W3214389889C41091548 @default.
• W3214389889 hasConceptScore W3214389889C54355233 @default.
• W3214389889 hasConceptScore W3214389889C60644358 @default.
• W3214389889 hasConceptScore W3214389889C71924100 @default.
• W3214389889 hasConceptScore W3214389889C86803240 @default.
• W3214389889 hasIssue "Supplement 1" @default.
• W3214389889 hasLocation W32143898891 @default.
• W3214389889 hasOpenAccess W3214389889 @default.
• W3214389889 hasPrimaryLocation W32143898891 @default.
• W3214389889 hasRelatedWork W1988919009 @default.
• W3214389889 hasRelatedWork W2079497260 @default.
• W3214389889 hasRelatedWork W2111612850 @default.
• W3214389889 hasRelatedWork W2922784218 @default.
• W3214389889 hasRelatedWork W2952198659 @default.
• W3214389889 hasRelatedWork W2963322175 @default.
• W3214389889 hasRelatedWork W3025843354 @default.
• W3214389889 hasRelatedWork W3045052814 @default.
• W3214389889 hasRelatedWork W3138862562 @default.
• W3214389889 hasRelatedWork W977645221 @default.
• W3214389889 hasVolume "138" @default.

• next